与结合组织疾病相关的间歇性肺病:在不断扩大的证据基础中,一种治疗方法
Michael Hong1,2, Elizabeth Veitch3, Sandhya Limaye1,2
1Department of Immunology, Concord Hospital, Sydney, New South Wales, Australia.
连接组织疾病相关的间歇性肺病 (CTD-ILD) 是一种复杂的肺部疾病. 新的临床试验证据指导了更新的管理策略,重点关注支持性护理和尽量减少副作用.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 连接组织疾病相关的间歇性肺病 (CTD-ILD) 涉及免疫介导的肺损伤.
- CTD-ILD可能导致呼吸衰竭,显著影响患者的发病率和死亡率.
- 包括全身性硬化症和类风湿性关节炎在内的各种CTD可以与ILD一起出现.
研究的目的:
- 审查CTD-ILD的新管理策略.
- 专注于来自最近临床试验和前性研究的证据.
- 突出支持性护理的重要性以及管理与治疗相关的不良影响.
主要方法:
- 对最近的临床试验和前性研究进行了全面的文献综述.
- 对药理管理选择的分析,包括皮质类固醇,免疫抑制剂和抗纤维菌剂.
- 在不断变化的证据背景下对治疗决策的评估.
主要成果:
- 最近的试验为CTD-ILD的治疗干预提供了新的见解.
- 治疗决策越来越多地以不同CTD-ILD亚型的具体证据为指导.
- 支持性护理和减少不良影响是管理的关键组成部分.
结论:
- 对CTD-ILD管理的证据库正在迅速扩大.
- 新的策略正在出现,超越了从系统性硬化症-ILD的推断.
- 整体的患者护理,解决复杂的肺病理和并发症,是必不可少的.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Cystic Fibrosis: Management
Sinus disease and chronic...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
COPD: Management Using Bronchodilators and Corticosteroids
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
